XPRIZE announced 20 Finalist teams today at an awards ceremony in Salt Lake City. Of the Finalists, 10 teams will be awarded $1 million each as Milestone 2 Awardees. These teams span four countries — the United States, South Korea, Japan, and China — reflecting the global scale of the race to solve aging. In addition to the $1 million milestone award, each Awardee receives access to key clinical testing resources, bringing total milestone funding to $10 million, to accelerate development and clinical testing of its therapeutic approach. Minicircle is among the 10 teams that have been named a finalist.

A gene therapy that instructs cells to produce more of an anti-ageing protein called klotho is about to be offered by a US company at overseas clinics to bypass FDA rules.

“The potential of today’s most cutting-edge genetic medicine to improve human health and extend lifespan is here, and we need human courage in order to actually grasp it,” he continued. “Every leap and great discovery in medical history has come not from bureaucratic caution, but from the courage to discover.” – Mac Davis

Mac Davis of Minicircle on the challenges and opportunities of a controversial new treatment.

One company that stands to benefit from the rise of freedom cities is Minicircle, a longevity biotech company focused on developing gene therapies to extend human lifespans.

Don’t Die: The Man Who Wants to Live Forever is Netflix’s new documentary film about Bryan Johnson’s anti-aging attempts, and here’s what the Minicircle gene therapy company actually is.

Kenneth Scott travels internationally for experimental treatments, doesn’t use soap, and spends hundreds of thousands of dollars on his quest for immortality